Track topics on Twitter Track topics that are important to you
Boehringer Ingelheim announced that patient enrollment has begun for its study to demonstrate that BI 695501, its adalimumab biosimilar candidate, is interchangeable with the U.S.-marketed formulation of Humira 40 mg/0.8 mL.The pharmacokinetics and clinical outcomes will be compared between patients with moderate-to-severe chronic plaque psoriasis receiving Humira (adalimumab, AbbVie) continuously and those who switch repeatedly between adalimumab and BI 695501, according to a news release. Safety, immunogenicity and efficacy also will be measured in the study.NEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...